Skip to main content
Premium Trial:

Request an Annual Quote

Bristol-Myers Squibb Licenses GeneGo's Software and Databases

NEW YORK (GenomeWeb News) - Bristol-Myers Squibb has licensed GeneGo’s software and database platforms for its pharmaceutical research programs, GeneGo said today.
Under the multi-year agreement, BMS will use "all major GeneGo products" for chemical and biological studies, GeneGo said. BMS researchers will use the company’s tools to analyze data and to build their own pathway maps using public, GeneGo, and proprietary data.
GeneGo said that BMS researchers will also use its products to overlay in-house interaction data over the company’s manually curated pathways.
GeneGo's software suite includes MetaCore, which is used to target and identify biomarkers for disease research; the MetaDrug platform, for studying metabolism and toxicity; and MetaBase, which holds data and information for the MetaCore product.
Financial terms of the agreement were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.